Central Serous Chorioretinopathy. Separation of retinal layers
Conditions
Interventions
finasteride 5 mg tablet, 1 tablet per day up to 3 months(intervention group)
no control group.
Treatment - Drugs
finasteride 5 mg tablet, 1 tablet per day up to 3 months(intervention group)
no control group
Sponsors
Shahid Sadoughi University of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility criteria:patients with chronic CSCR, which was defined in this study as 1) the presence of subretinal fluid, as determined by spectraldomain OCT;2)the subretinal fluid must have been present for at least 3 months or there was a recurrence of subretinal fluid in ipsilateral eye within the past 3 months. exclusion criteria:corticosteroid use,CNV or other ocular disease that disturb the study outcome,pregnant and nursery women
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity. Timepoint: by the intervention initiation,15 days,1,2 and 3 months after intervention,3months after discontinuation of intervention. Method of measurement: Snellen chart.;Central macular thickness. Timepoint: by the intervention initiation,15 days,1,2 and 3 months after intervention,3months after discontinuation of intervention. Method of measurement: spectral domain OCT.;Subretinal fluid volume. Timepoint: by the intervention initiation,15 days,1,2 and 3 months after intervention,3months after discontinuation of intervention. Method of measurement: spectral domain OCT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects(decreased libido,impotence,improper ejaculation,postural hypotension,dizziness). Timepoint: 15 days,1,2 and 3 months after intervention. Method of measurement: pation history taking. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahere Rezaee
Shahid Sadoughi University of Medical Science
Outcome results
None listed